Seattle biotech incubator helps another young fledgling to fly

Seattle biotechnology startup Allozyne closed on its first funding round only three weeks ago, but its scientists are already moving into state-of-the-art lab space.

Accelerator, the aptly named Seattle biotech incubator that’s officially announcing Allozyne today, has made a franchise of quickly bringing promising science into development while freeing scientists from the more mundane burdens of launching a business.

"It saves me from doing the part of the job that I don’t like to do," said Allozyne’s chief scientific officer Kenneth Grabstein, a veteran of Corixa and Immunex.

The work Grabstein likes, in Allozyne’s case, is developing a technology that could improve a range of protein-based drug therapies.

By Benjamin J. Romano

Seattle Times business reporter

Full Story: http://seattletimes.nwsource.com/html/businesstechnology/2002602995_accelerator04.html